'For
the quarter ending March 2024, consolidated Net sales (including other operating income) of Ipca Laboratories has increased 34.49% to Rs 2033.01 crore compared to quarter ended March 2023. Operating profit margin has jumped from 11.98% to 15.83%, leading to 77.81% rise in operating profit to Rs 321.90 crore. Raw material cost as a % of total sales (net of stock adjustments) decreased from 28.85% to 27.96%. Purchase of finished goods cost fell from 6.88% to 5.37%. Employee cost increased from 22.86% to 23.06%. Other expenses fell from 28.78% to 27.67%. Other income fell 48.01% to Rs 18.92 crore. PBIDT rose 56.75% to Rs 340.82 crore. Provision for interest rose 59.19% to Rs 29.37 crore. Loan funds declined from Rs 1,481.27 crore as of 31 March 2023 to Rs 1,438.36 crore as of 31 March 2024. Inventories rose to Rs 2,469.56 crore as of 31 March 2024 from...
Pleaselogin & subscribe to view the full report.
More Reports
|
|